Blocknomi
TLDR Amgen (AMGN) stock falls 0.77% despite promising Phase 3 dazodalibep trial results. Amgen’s Phase 3 trial meets primary endpoints, offering hope for Sjögren’s patients. Dazodalibep significantly reduces systemic disease…
Related articles
-
Strategy’s STRC nears $100 level that could reopen a Bitcoin funding channel
CryptoSlate Published 29.10.2026 14:30
-
Binance Hacker Moves All $293M in Stolen XRP as $242M Slips out Through Tron
Bitcoin.com Published 02.11.2026 07:30
-
Brazil’s Mercado Bitcoin Freezes Deposits and Withdrawals Due to Ongoing Security Incident, Losses Estimated Near $40 Million
Bitcoin Magazine Published 02.11.2026 16:09
-
Bitcoin Miner Riot Platforms Sells $750M in BTC as Hut 8 Dumps $250M
Bitcoin.com Published 04.11.2026 19:55
-
$250M FalconX Facility Powers Ibis Push Into Onchain Credit
Bitcoin.com Published 28.10.2026 22:30
-
What Would Happen to the Crypto Market if Binance Went Bankrupt? 3 AIs Speculate
CryptoPotato Published 06.11.2026 05:05
-
Binance Publishes New Proof-of-Reserves Snapshot Following October Attack
NewsBTC Published 03.11.2026 18:00
-
OCC Proposes Weekly and Quarterly Reporting Forms for Stablecoin Issuers
NewsBTC Published 28.10.2026 16:00